Exploring the effect of erythropoietin on mortality using USRDS data

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 6, 2013, Pages 593-606

  Yang, Wei ^a   Joffe, Marshall M ^a   Feldman, Harold I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Confounding by indication; Erythropoietin; Intention to treat analysis; Mortality; Pharmacoepidemiology; Time dependent confounding; USRDS

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; ARTICLE; DISEASE SEVERITY; DRUG EFFECT; FOLLOW UP; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HEMATOCRIT; HUMANS; MALE; MEDICAL RECORD LINKAGE; MORTALITY; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY; UNITED STATES;

EID: 84878772720     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3452     Document Type: Article

References (47)

1. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med Aug 27 1998; 339(9): 584-590.
2. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med Nov 16 2006; 355(20): 2085-2098.
3. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med Nov 16 2006; 355(20): 2071-2084.
4. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med Nov 19 2009; 361(21): 2019-2032.
5. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis: Offic J Natl Kidney Found Nov 2004; 44(5): 866-876.
6. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. N Eng J Med 2010; 363(12): 1146-1155.
7. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiol Drug Saf 2003; 12(7): 551-558.
8. Salas M, Hofman A, Stricker BHC. Confounding by indication: An example of variation in the use of epidemiologic terminology. Am J Epidemiol Jun 1 1999; 149(11): 981-983.
9. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983; 2(2): 267-271.
10. Greenland S, Neutra R. Control of Confounding in the Assessment of Medical Technology. Int J Epidemiol 1980; 9(4): 361-367.
11. Bradbury BD, Do TP, Winkelmayer WC, Critchlow CW, Brookhart MA. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11g/dL. Pharmacoepidemiol Drug Saf Oct 2009; 18(10): 932-940.
12. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology Sep 2000; 11(5): 550-560.
13. Robins JM, Blevins D, Ritter G, Wulfsohn M. G-Estimation of the Effect of Prophylaxis Therapy for Pneumocystis-Carinii Pneumonia on the Survival of Aids Patients. Epidemiology Jul 1992; 3(4): 319-336.
14. Robins J. The Control of Confounding by Intermediate Variables. Stat Med Jun 1989; 8(6): 679-701.
15. Hernan MA, Alonso A, Logan R, et al. Observational Studies Analyzed Like Randomized Experiments An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease. Epidemiology Nov 2008; 19(6): 766-779.
16. USRDS: the United States Renal Data System. Am J Kidney Dis: Offic J Natl Kidney Found Dec 2003; 42(6 Suppl 5): 1-230.
17. Imai K, van Dyk DA. Causal inference with general treatment regimes: Generalizing the propensity score. J Am Stat Assoc Sep 2004; 99(467): 854-866.
18. Robins JM, Finkelstein DM. Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log-Rank Tests. Biometrics 2000; 56(3): 779-788.
19. Greenland S. Dose-Response and Trend Analysis in Epidemiology - Alternatives to Categorical Analysis. Epidemiology Jul 1995; 6(4): 356-365.
20. Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for Causal Effects. Biometrika 1983; 70(1): 41-55.
21. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology Sep 2000; 11(5): 561-570.
22. Hernan MA, Robins JM, Rodriguez LAG. Statistical issues arising in the Women's Health Initiative - Discussion. Biometrics Dec 2005; 61(4): 922-930.
23. Cox DR. Regression Models and Life-Tables. J Royal Stat Soc Series B (Methodological) 1972; 34(2): 187-220.
24. Efron B, Tibshirani R. An Introduction to the Bootstrap. Chapman & Hall: New York, 1993.
25. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. Offic J Am Soc Clin Oncol Mar 20 2007; 25(9): 1027-1032.
26. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol Aug 2003; 4(8): 459-460.
27. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet Oct 18 2003; 362(9392): 1255-1260.
28. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst May 17 2006; 98(10): 708-714.
29. Gail MH, Byar DP. Variance Calculations for Direct Adjusted Survival Curves, with Applications to Testing for No Treatment Effect. Biometrical J 1986; 28(5): 587-599.
30. Lane PW, Nelder JA. Analysis of Covariance and Standardization as Instances of Prediction. Biometrics 1982; 38(3): 613-621.
31. Joffe MM, Greenland S. Standardized Estimates from Categorical Regression-Models. Stat Med Oct 15 1995; 14(19): 2131-2141.
32. van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol Jan 2008; 4(1): 47-57.
33. Greenwood RN, Ronco C, Gastaldon F, et al. Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance. Kidney Int Suppl Nov 2003; 87: S78-86.
34. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA Mar 3 2010; 303(9): 857-864.
35. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA Feb 9 1990; 263(6): 825-830.
36. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol Feb 2000; 11(2): 335-342.
37. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int May 2003; 63(5): 1908-1914.
38. Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol Oct 2004; 57(10): 1086-1095.
39. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood May 1 2000; 95(9): 2983-2989.
40. Kirkeby A, Torup L, Bochsen L, et al. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Thromb Haemost Apr 2008; 99(4): 720-728.
41. Patel TV, Mittal BV, Keithi-Reddy SR, Duffield JS, Singh AK. Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract 2008; 110(4): c244-250.
42. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis: Offic J Natl Kidney Found May 1999; 33(5): 821-828.
43. Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens Sep 2010; 19(5): 420-424.
44. Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif 2010; 29(2): 86-92.
45. Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis: Offic J Natl Kidney Found Nov 2008; 52(5): 907-915.
46. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol: JASN Jun 2004; 15(6): 1623-1632.
47. Joffe MM, Yang W, Feldman HI. Selective Ignorability Assumptions in Causal Inference. Int J Biostat 2010; 6(2): Article 11.